Ghost Tree Capital’s Akero Therapeutics AKRO Stock Holding History

Ghost Tree Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250,000	Closed	-$12.6M	–	54
2023 Q3	$12.6M	Buy	+250,000	New	+$11.6M	4.16%	5

Other funds holding AKRO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ghost Tree Capital's AKRO Position: Q4 2023 in Review

Ghost Tree Capital sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 115,000 shares — an estimated $5.82M sold.

Ghost Tree Capital first reported a position in AKRO in Q4 2022 and held it in 4 quarters. The position peaked at $16.8M in Q2 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

Ghost Tree Capital reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
Ghost Tree Capital sold 115,000 Akero Therapeutics shares in Q4 2023, an estimated $5.82M.
Ghost Tree Capital first reported a position in Akero Therapeutics in Q4 2022 and held it in 4 quarters.
Ghost Tree Capital's Akero Therapeutics position peaked at $16.8M in Q2 2023.
157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.